Alnylam Pharma Q1 Onpattro sales up 154%; guidance lowered

Alnylam Pharmaceuticals (ALNY) Q1 results:

Revenues: $99.5M (+198.8%); Onpattro sales: $66.7M (+153.6); Givlaari sales: $5.3M; collaborator revenue: $27.5M.

Net loss: ($182.2M) (-0.2%); loss/share: ($1.62) (+6.4%); non-GAAP Net loss: ($171.8M) (-14.6%); non-GAAP loss/share: ($1.52) (-7.0%).

2020 guidance: Onpattro sales: $270M – 300M from $285M – 315M; collaborator revenue: $100M – 150M (unch).

Previously: Alnylam Pharmaceuticals EPS misses by $0.01, beats on revenue (May 6)

https://seekingalpha.com/news/3570092-alnylam-pharma-q1-onpattro-sales-up-154-guidance-lowered